Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis
Launched by AMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTER · Feb 1, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness and tolerability of Sucrosomial Iron compared to traditional Oral Iron Sulfate for treating Iron Deficiency Anemia in patients with Ulcerative Colitis. Iron Deficiency Anemia is a condition where your body doesn’t have enough iron, which can lead to fatigue and weakness. The trial aims to find out which iron treatment works better and is easier for patients to take.
To be eligible for this trial, participants must be adults over 18 years old who have been diagnosed with Ulcerative Colitis and have confirmed Iron Deficiency Anemia. This means their hemoglobin levels (a measure of red blood cells) should be above 8 grams per deciliter, but below 12 for women and below 13 for men. Participants can expect regular check-ins and assessments during the trial to monitor their health and response to the treatments. It’s important to know that certain conditions, such as severe anemia, recent hospitalizations, or specific health issues, may prevent someone from participating.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age above 18
- • Confirmed diagnosis of Ulcerative Colitis
- • Proven Iron Deficiency Anemia (Hb \< 12 for females and Hb \< 13 for males AND iron saturation \<20%)
- • Hemoglobin level \> 8g/dl
- Exclusion Criteria:
- • Age below 18
- • Hemoglobin level \< 8g/dl
- • Recently hospitalized for disease flare (within 3 months)
- • Hemoglobinopathies (including thalassemia)
- • Isolated proctitis
- • Indeterminate colitis
- • Known liver or kidney disease
- • Known Celiac Disease
- • Extensive small bowel resection
- • Use of anticoagulants or aspirin
- • Known intolerance to oral iron therapy
- • Uninvestigated anemia
- • Pregnant or lactating women
- • Known hypersensitivity to iron sulfate
- • Transfusion in the past 4 weeks
- • Erythropoetin within the last 8 weeks
- • Rheumatoid Arthritis
- • History of menometrorrhagia or frequent epistaxis
About American University Of Beirut Medical Center
The American University of Beirut Medical Center (AUBMC) is a leading academic medical institution in the Middle East, dedicated to advancing healthcare through innovative research, education, and clinical excellence. As a prominent sponsor of clinical trials, AUBMC integrates cutting-edge scientific inquiry with patient-centered care to enhance therapeutic options and improve health outcomes. With a commitment to ethical standards and regulatory compliance, AUBMC collaborates with multidisciplinary teams to conduct rigorous trials that contribute to the global medical knowledge base and address critical health challenges in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beirut, , Lebanon
Patients applied
Trial Officials
Ala Sharara, MD
Principal Investigator
American University of Beirut Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials